Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK.

Mol Cancer Ther. 2019 May;18(5):969-979. doi: 10.1158/1535-7163.MCT-18-0770. Epub 2019 Mar 29.

PMID:
30926640
2.

Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.

Villar-Prados A, Wu SY, Court KA, Ma S, LaFargue C, Chowdhury MA, Engelhardt MI, Ivan C, Ram PT, Wang Y, Baggerly K, Rodriguez-Aguayo C, Lopez-Berestein G, Ming-Yang S, Maloney DJ, Yoshioka M, Strovel JW, Roszik J, Sood AK.

Mol Cancer Ther. 2019 Feb;18(2):421-436. doi: 10.1158/1535-7163.MCT-18-0365. Epub 2018 Nov 12.

PMID:
30420565
3.

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Allen JK, Armaiz-Pena GN, Nagaraja AS, Sadaoui NC, Ortiz T, Dood R, Ozcan M, Herder DM, Haemmerle M, Gharpure KM, Rupaimoole R, Previs RA, Wu SY, Pradeep S, Xu X, Han HD, Zand B, Dalton HJ, Taylor M, Hu W, Bottsford-Miller J, Moreno-Smith M, Kang Y, Mangala LS, Rodriguez-Aguayo C, Sehgal V, Spaeth EL, Ram PT, Wong STC, Marini FC, Lopez-Berestein G, Cole SW, Lutgendorf SK, De Biasi M, Sood AK.

Cancer Res. 2018 Jun 15;78(12):3233-3242. doi: 10.1158/0008-5472.CAN-16-1701. Epub 2018 Apr 16.

4.

Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth.

Yang L, Achreja A, Yeung TL, Mangala LS, Jiang D, Han C, Baddour J, Marini JC, Ni J, Nakahara R, Wahlig S, Chiba L, Kim SH, Morse J, Pradeep S, Nagaraja AS, Haemmerle M, Kyunghee N, Derichsweiler M, Plackemeier T, Mercado-Uribe I, Lopez-Berestein G, Moss T, Ram PT, Liu J, Lu X, Mok SC, Sood AK, Nagrath D.

Cell Metab. 2016 Nov 8;24(5):685-700. doi: 10.1016/j.cmet.2016.10.011.

5.

Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p.

Seviour EG, Sehgal V, Mishra D, Rupaimoole R, Rodriguez-Aguayo C, Lopez-Berestein G, Lee JS, Sood AK, Kim MP, Mills GB, Ram PT.

Oncogene. 2017 Mar;36(10):1339-1350. doi: 10.1038/onc.2016.308. Epub 2016 Sep 26.

6.

A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.

Wu SY, Rupaimoole R, Shen F, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han HD, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK.

Nat Commun. 2016 Apr 4;7:11169. doi: 10.1038/ncomms11169.

7.

Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism.

Zhao H, Yang L, Baddour J, Achreja A, Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, San Lucas FA, Alvarez H, Gupta S, Maiti SN, Cooper L, Peehl D, Ram PT, Maitra A, Nagrath D.

Elife. 2016 Feb 27;5:e10250. doi: 10.7554/eLife.10250.

8.

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT.

Oncogene. 2016 Feb 11;35(6):801. doi: 10.1038/onc.2015.177. No abstract available.

PMID:
26865225
9.

Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers.

Sehgal V, Seviour EG, Moss TJ, Mills GB, Azencott R, Ram PT.

PLoS One. 2015 Oct 27;10(10):e0140072. doi: 10.1371/journal.pone.0140072. eCollection 2015.

10.

Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers.

Moss TJ, Luo Z, Seviour EG, Sehgal V, Lu Y, Hill SM, Rupaimoole R, Lee JS, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Azencott R, Gray JW, Mukherjee S, Mills GB, Ram PT.

NPJ Syst Biol Appl. 2015 Sep 28;1:15001. doi: 10.1038/npjsba.2015.1. eCollection 2015.

11.

The ZNF304-integrin axis protects against anoikis in cancer.

Aslan B, Monroig P, Hsu MC, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, Rupaimoole R, Nagaraja AS, Mangala S, Han HD, Yuca E, Wu SY, Ivan C, Moss TJ, Ram PT, Wang H, Gol-Chambers A, Ozkayar O, Kanlikilicer P, Fuentes-Mattei E, Kahraman N, Pradeep S, Ozpolat B, Tucker S, Hung MC, Baggerly K, Bartholomeusz G, Calin G, Sood AK, Lopez-Berestein G.

Nat Commun. 2015 Jun 17;6:7351. doi: 10.1038/ncomms8351.

12.

Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.

Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T, Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, Azencot R, Lopez-Berestein G, Rodriguez-Aguayo C, Roopaimoole R, Pecot CV, Sood AK, Mukherjee S, Gray JW, Mills GB, Ram PT.

Oncogene. 2016 Feb 11;35(6):691-701. doi: 10.1038/onc.2014.469. Epub 2015 Feb 2. Erratum in: Oncogene. 2016 Feb 11;35(6):801. Pecot, C [Corrected to Pecot, C V].

13.

Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas.

Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB.

Nat Commun. 2015 Jan 28;6:4852. doi: 10.1038/ncomms5852. No abstract available.

PMID:
25629879
14.

A pan-cancer proteomic perspective on The Cancer Genome Atlas.

Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB.

Nat Commun. 2014 May 29;5:3887. doi: 10.1038/ncomms4887. Erratum in: Nat Commun. 2015;6:4852.

15.

Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.

Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, Lopez-Berestein G, Liu J, Tsukamoto T, Sood AK, Ram PT, Nagrath D.

Mol Syst Biol. 2014 May 5;10:728. doi: 10.1002/msb.20134892.

16.

Mapping network motif tunability and robustness in the design of synthetic signaling circuits.

Iadevaia S, Nakhleh LK, Azencott R, Ram PT.

PLoS One. 2014 Mar 18;9(3):e91743. doi: 10.1371/journal.pone.0091743. eCollection 2014.

17.

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK.

Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.

18.

A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.

Nishikawa T, Bellance N, Damm A, Bing H, Zhu Z, Handa K, Yovchev MI, Sehgal V, Moss TJ, Oertel M, Ram PT, Pipinos II, Soto-Gutierrez A, Fox IJ, Nagrath D.

J Hepatol. 2014 Jun;60(6):1203-11. doi: 10.1016/j.jhep.2014.02.014. Epub 2014 Feb 26.

19.

Cancer Systems Biology: a peek into the future of patient care?

Werner HM, Mills GB, Ram PT.

Nat Rev Clin Oncol. 2014 Mar;11(3):167-76. doi: 10.1038/nrclinonc.2014.6. Epub 2014 Feb 4. Review.

20.

Network Motifs in JNK Signaling.

Sehgal V, Ram PT.

Genes Cancer. 2013 Sep;4(9-10):409-13. doi: 10.1177/1947601913507577. Review.

21.

Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.

Matsuo K, Nishimura M, Komurov K, Shahzad MM, Ali-Fehmi R, Roh JW, Lu C, Cody DD, Ram PT, Loizos N, Coleman RL, Sood AK.

Gynecol Oncol. 2014 Jan;132(1):166-75. doi: 10.1016/j.ygyno.2013.10.027. Epub 2013 Oct 29.

22.

Tumour angiogenesis regulation by the miR-200 family.

Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, Bottsford-Miller J, Liu Y, Kim SB, Unruh A, Gonzalez-Villasana V, Huang L, Zand B, Moreno-Smith M, Mangala LS, Taylor M, Dalton HJ, Sehgal V, Wen Y, Kang Y, Baggerly KA, Lee JS, Ram PT, Ravoori MK, Kundra V, Zhang X, Ali-Fehmi R, Gonzalez-Angulo AM, Massion PP, Calin GA, Lopez-Berestein G, Zhang W, Sood AK.

Nat Commun. 2013;4:2427. doi: 10.1038/ncomms3427.

23.

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.

Komurov K, Tseng JT, Muller M, Seviour EG, Moss TJ, Yang L, Nagrath D, Ram PT.

Mol Syst Biol. 2012;8:596. doi: 10.1038/msb.2012.25.

24.

NetWalker: a contextual network analysis tool for functional genomics.

Komurov K, Dursun S, Erdin S, Ram PT.

BMC Genomics. 2012 Jun 25;13:282. doi: 10.1186/1471-2164-13-282.

25.

Bioinformatics and systems biology.

Ram PT, Mendelsohn J, Mills GB.

Mol Oncol. 2012 Apr;6(2):147-54. doi: 10.1016/j.molonc.2012.01.008. Epub 2012 Feb 17. Review.

26.

Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.

Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK.

J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.

27.

Targeting SRC in mucinous ovarian carcinoma.

Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK.

Clin Cancer Res. 2011 Aug 15;17(16):5367-78. doi: 10.1158/1078-0432.CCR-10-3176. Epub 2011 Jul 7.

28.

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling.

Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB.

Oncogene. 2011 Nov 10;30(45):4567-77. doi: 10.1038/onc.2011.164. Epub 2011 Jun 13.

29.

Patterns of human gene expression variance show strong associations with signaling network hierarchy.

Komurov K, Ram PT.

BMC Syst Biol. 2010 Nov 12;4:154. doi: 10.1186/1752-0509-4-154.

30.

Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data.

Komurov K, White MA, Ram PT.

PLoS Comput Biol. 2010 Aug 19;6(8). pii: e1000889. doi: 10.1371/journal.pcbi.1000889.

31.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132.

32.

Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.

Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT.

Cancer Res. 2010 Sep 1;70(17):6704-14. doi: 10.1158/0008-5472.CAN-10-0460. Epub 2010 Jul 19.

33.

Rapidly exploring structural and dynamic properties of signaling networks using PathwayOracle.

Ruths D, Nakhleh L, Ram PT.

BMC Syst Biol. 2008 Aug 19;2:76. doi: 10.1186/1752-0509-2-76.

34.

The signaling petri net-based simulator: a non-parametric strategy for characterizing the dynamics of cell-specific signaling networks.

Ruths D, Muller M, Tseng JT, Nakhleh L, Ram PT.

PLoS Comput Biol. 2008 Feb 29;4(2):e1000005. doi: 10.1371/journal.pcbi.1000005.

35.

Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R.

Muller M, Obeyesekere M, Mills GB, Ram PT.

FASEB J. 2008 May;22(5):1393-403. doi: 10.1096/fj.07-9100com. Epub 2008 Jan 2.

PMID:
18171696
36.

An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.

Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R, Ram PT.

Mol Cell Endocrinol. 2007 May 30;270(1-2):50-6. Epub 2007 Feb 17.

PMID:
17374439
37.

Hypothesis generation in signaling networks.

Ruths DA, Nakhleh L, Iyengar MS, Reddy SA, Ram PT.

J Comput Biol. 2006 Nov;13(9):1546-57.

PMID:
17147477
38.

Exploiting the PI3K/AKT pathway for cancer drug discovery.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB.

Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. Review.

PMID:
16341064
39.

Formation of regulatory patterns during signal propagation in a Mammalian cellular network.

Ma'ayan A, Jenkins SL, Neves S, Hasseldine A, Grace E, Dubin-Thaler B, Eungdamrong NJ, Weng G, Ram PT, Rice JJ, Kershenbaum A, Stolovitzky GA, Blitzer RD, Iyengar R.

Science. 2005 Aug 12;309(5737):1078-83.

40.

The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3.

He JC, Gomes I, Nguyen T, Jayaram G, Ram PT, Devi LA, Iyengar R.

J Biol Chem. 2005 Sep 30;280(39):33426-34. Epub 2005 Jul 26.

41.

Quantitative information management for the biochemical computation of cellular networks.

Campagne F, Neves S, Chang CW, Skrabanek L, Ram PT, Iyengar R, Weinstein H.

Sci STKE. 2004 Aug 24;2004(248):pl11.

PMID:
15340175
42.
43.

G protein pathways.

Neves SR, Ram PT, Iyengar R.

Science. 2002 May 31;296(5573):1636-9. Review.

PMID:
12040175
44.

Involvement of the mt1 melatonin receptor in human breast cancer.

Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, Hill SM.

Cancer Lett. 2002 May 28;179(2):141-50.

PMID:
11888668
45.

Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells.

Kiefer T, Ram PT, Yuan L, Hill SM.

Breast Cancer Res Treat. 2002 Jan;71(1):37-45.

PMID:
11859872
46.

Overexpression of tightly regulated proteins: protein phosphatase 2A overexpression in NIH 3T3 cells.

Ram PT.

Methods Enzymol. 2002;345:551-5. No abstract available.

PMID:
11665638
47.

Transcriptional repression of RORalpha activity in human breast cancer cells by melatonin.

Dai J, Ram PT, Yuan L, Spriggs LL, Hill SM.

Mol Cell Endocrinol. 2001 May 15;176(1-2):111-20.

PMID:
11369450
48.
49.

Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin.

Ram PT, Yuan L, Dai J, Kiefer T, Klotz DM, Spriggs LL, Hill SM.

J Pineal Res. 2000 May;28(4):210-8.

PMID:
10831156
50.

Melatonin synergizes with retinoic acid in the prevention and regression of breast cancer.

Hill SM, Teplitzky S, Ram PT, Kiefer T, Blask DE, Spriggs LL, Eck KM.

Adv Exp Med Biol. 1999;460:345-62. Review. No abstract available.

PMID:
10810532

Supplemental Content

Loading ...
Support Center